← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ANTIMETABOLITES › Purine analogues
nelarabine
L01BB07
Forms & Strengths
- Solution for injection: 5mg/mL, 50mg/10mL single-dose vial
- Solution for injection must be diluted prior to administration
Adult Dosing
- 1500mg/m2 IV on days 1, 3, and 5, every 28 days for leukemia treatment
- Dosing should be individualized and adjusted based on patient response and tolerance
Pediatric Dosing
- 650mg/m2 IV on days 1, 3, and 5, every 28 days for T-cell ALL/LBL treatment
- Pediatric dosing should be adjusted according to the patient's body surface area
Indications
- Treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)
- Relapsed or refractory disease
Mechanism of Action
- Nucleoside analog that inhibits DNA synthesis
- Metabolized to 9-β-D-arabinofuranosylguanine (ara-G) which incorporates into DNA and disrupts DNA synthesis
Contraindications
- Hypersensitivity to nelarabine or its components
- Severe hepatic impairment
Adverse Reactions
- Neurotoxicity, including somnolence, fatigue, and peripheral neuropathy
- Hematologic toxicity, including anemia, thrombocytopenia, and neutropenia
- Nausea, vomiting, and diarrhea
Drug Interactions
- Other neurotoxic or hepatotoxic agents may increase the risk of adverse reactions
- Fluconazole and other inhibitors of CYP3A4/5 may increase nelarabine concentrations
Curated Content: Needs Vetting Before Put to Clinical Use